{"id":829408,"date":"2025-03-25T08:11:54","date_gmt":"2025-03-25T12:11:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/"},"modified":"2025-03-25T08:11:54","modified_gmt":"2025-03-25T12:11:54","slug":"nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/","title":{"rendered":"NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025)"},"content":{"rendered":"
\n

SANTA ANA, Calif., March 25, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (\u201cNKGen\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (\u201cNK\u201d) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (\u201cAD\/PD\u2122 2025\u201d) taking place online and in Vienna, Austria from April 1 \u2013 5, 2025.<\/p>\n

AD\/PD\u2122 2025 is a premier event bringing together top international experts to discuss the latest advancements in Alzheimer\u2019s and Parkinson\u2019s research, clinical trials, and treatments. With over 4,700 participants from 70+ countries and 2,250 abstracts in 2024, it offers a platform for groundbreaking discoveries from the leading experts in the field.<\/p>\n

\n
\n Presentation Details<\/u>
\n <\/strong>
\n :<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Title<\/strong>:<\/td>\nPreliminary Cognitive Improvement in Phase 1 Cohort of Moderate Alzheimer\u2019s Disease Subjects Treated with Autologous Natural Killer Cells (Troculeucel; SNK01)<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Session Name:<\/strong>\n <\/td>\n7540 \u2013 Advances in AD Drug Development 02<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Session Type:<\/strong>\n <\/td>\nSymposium<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Presentation Date:<\/strong>\n <\/td>\nSaturday, April 5, 2025, at 5:10 pm \u2013 5:25 pm CEST<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Room:<\/strong>\n <\/td>\nHall E<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

Dr. Song\u2019s presentation will focus on the three-month cognitive and biomarker results from the Phase 1 cohort of the Phase 1\/2a clinical trial for troculeucel NK cell therapy in moderate Alzheimer\u2019s disease, as well as new data from the six-month analysis of this cohort.<\/p>\n

Previously disclosed data for troculeucel in Alzheimer\u2019s disease and solid tumors can be found on the Scientific Publications page of the Company\u2019s website at https:\/\/nkgenbiotech.com\/scientific-publications\/<\/a>. News releases containing troculeucel clinical trial updates and regulatory approvals can be found on the News page of the Company\u2019s website at https:\/\/nkgenbiotech.com\/news\/<\/a>.<\/p>\n

\n About Troculeucel<\/strong>
\n
Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name (\u201cINN\u201d) for SNK01 assigned by the World Health Organization (\u201cWHO\u201d). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen\u2019s journey toward bringing this therapy to market.<\/p>\n

\n About NKGen Biotech<\/strong>
\n
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit\u00a0www.nkgenbiotech.com<\/a>.<\/p>\n

\n Forward-Looking Statements\u00a0<\/strong>
\n
Statements contained in this press release may contain \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as \u201canticipate\u201d, \u201cbelieve\u201d, \u201ccould\u201d, \u201ccontinue\u201d, \u201cexpect\u201d, \u201cestimate\u201d, \u201cmay\u201d, \u201cplan\u201d, \u201coutlook\u201d, \u201cfuture\u201d and \u201cproject\u201d and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company\u2019s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company\u2019s plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company\u2019s expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company\u2019s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen\u2019s ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption \u201cRisk Factors\u201d and elsewhere in the Company\u2019s filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission\u2019s website at www.sec.gov and on the Company\u2019s website under the subheading \u201cInvestors\u2014Financial and Filings\u201d. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/p>\n

\n Internal Contact:<\/strong>
\n
Denise Chua, MBA, CLS, MLS (ASCP)
SVP, Corporate Affairs
949-396-6830
dchua@nkgenbiotech.com<\/a><\/p>\n

\n External Contacts:<\/strong>
\n
Kevin Gardner
Managing Director
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SANTA ANA, Calif., March 25, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (\u201cNKGen\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (\u201cNK\u201d) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (\u201cAD\/PD\u2122 2025\u201d) taking place online and in Vienna, Austria from April 1 \u2013 5, 2025. AD\/PD\u2122 2025 is a premier event bringing together top international experts to discuss the latest advancements in Alzheimer\u2019s and Parkinson\u2019s research, clinical trials, and treatments. With over 4,700 participants from 70+ countries and 2,250 abstracts in 2024, it … <\/p>\n

Continue reading “NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829408","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SANTA ANA, Calif., March 25, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (\u201cNKGen\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (\u201cNK\u201d) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (\u201cAD\/PD\u2122 2025\u201d) taking place online and in Vienna, Austria from April 1 \u2013 5, 2025. AD\/PD\u2122 2025 is a premier event bringing together top international experts to discuss the latest advancements in Alzheimer\u2019s and Parkinson\u2019s research, clinical trials, and treatments. With over 4,700 participants from 70+ countries and 2,250 abstracts in 2024, it … Continue reading "NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T12:11:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODQ3MCM2ODE3NDkyIzUwMDA3MDg1OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\\\/PD\u2122 2025)\",\"datePublished\":\"2025-03-25T12:11:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\\\/\"},\"wordCount\":864,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5ODQ3MCM2ODE3NDkyIzUwMDA3MDg1OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\\\/\",\"name\":\"NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\\\/PD\u2122 2025) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5ODQ3MCM2ODE3NDkyIzUwMDA3MDg1OA==\",\"datePublished\":\"2025-03-25T12:11:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5ODQ3MCM2ODE3NDkyIzUwMDA3MDg1OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5ODQ3MCM2ODE3NDkyIzUwMDA3MDg1OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\\\/PD\u2122 2025)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/","og_locale":"en_US","og_type":"article","og_title":"NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025) - Market Newsdesk","og_description":"SANTA ANA, Calif., March 25, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (\u201cNKGen\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (\u201cNK\u201d) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (\u201cAD\/PD\u2122 2025\u201d) taking place online and in Vienna, Austria from April 1 \u2013 5, 2025. AD\/PD\u2122 2025 is a premier event bringing together top international experts to discuss the latest advancements in Alzheimer\u2019s and Parkinson\u2019s research, clinical trials, and treatments. With over 4,700 participants from 70+ countries and 2,250 abstracts in 2024, it … Continue reading \"NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T12:11:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODQ3MCM2ODE3NDkyIzUwMDA3MDg1OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025)","datePublished":"2025-03-25T12:11:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/"},"wordCount":864,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODQ3MCM2ODE3NDkyIzUwMDA3MDg1OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/","name":"NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODQ3MCM2ODE3NDkyIzUwMDA3MDg1OA==","datePublished":"2025-03-25T12:11:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODQ3MCM2ODE3NDkyIzUwMDA3MDg1OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODQ3MCM2ODE3NDkyIzUwMDA3MDg1OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nkgen-biotech-to-present-updated-troculeucel-data-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-ad-pd-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829408"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829408\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}